Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 75Breast Neoplasms 46Colorectal Neoplasms 42Neoplasms 41Neoplasm Metastasis 34Melanoma 33Multiple Myeloma 31Prostatic Neoplasms 29Stomach Neoplasms 26Recurrence 26Lung Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Pancreatic Neoplasms 25Carcinoma, Renal Cell 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Ovarian Neoplasms 22Lymphoma, Large B-Cell, Diffuse 22Triple Negative Breast Neoplasms 21Lymphoma, Non-Hodgkin 21Lymphoma, Follicular 21Leukemia, Myeloid, Acute 21Glioblastoma 20Leukemia, Lymphocytic, Chronic, B-Cell 19Uterine Cervical Neoplasms 16Myelodysplastic Syndromes 16Lymphoma 16Colonic Neoplasms 15Carcinoma, Transitional Cell 15Lymphoma, Mantle-Cell 14Hematologic Neoplasms 14

Interventions

trastuzumab deruxtecan 1toripalimab 1pertuzumab 1pembrolizumab 1atezolizumab 1Trastuzumab 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Solid Cancer × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡